Raaj Medisafe India Limited has successfully completed the allotment of 32,75,000 equity shares through preferential issue following the board meeting held on March 26, 2026. The pharmaceutical company had previously announced this board meeting on March 20, 2026, in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Board Meeting Outcome

The board meeting was conducted at the company's registered office and concluded with the approval of the preferential share allotment. The meeting details and outcomes demonstrate the company's commitment to regulatory compliance and strategic capital raising.

Share Allotment Details

The company successfully allotted shares to 17 non-promoter investors, raising significant capital for business operations. The allotment was conducted on a preferential basis with cash consideration, and the new shares will rank pari-passu with existing equity shares.

Regulatory Compliance Framework

Raaj Medisafe India Limited received in-principle approval from BSE Limited on March 12, 2026, for the preferential issue. The company has committed to filing the listing approval application for the newly allotted shares in due course, maintaining full compliance with regulatory requirements.

The announcement was signed by Arpit Bangur, Managing Director with DIN 02600716, and communicated to the Bombay Stock Exchange Limited. The company's registered office is located at 75/2 and 3, Industrial Area, Maksi Road, Ujjain-456010, where the board meeting was conducted.

Strategic Capital Raising Initiative

The preferential allotment represents a significant capital raising initiative that will strengthen the company's financial position. The shares were issued under Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and applicable provisions of Companies Act 2013.

The company has ensured complete transparency by providing detailed disclosures as required under Regulation 30 of the Listing Regulations and SEBI Circular on Continuous Disclosure. The successful completion of this preferential issue demonstrates investor confidence in the pharmaceutical company's growth prospects and business strategy.

Raaj Medisafe India Limited delivered impressive financial performance in Q3FY26, demonstrating strong operational efficiency and market demand across its business segments. The company's latest quarterly results highlight significant growth momentum in both revenue generation and profitability metrics.

Financial Performance Overview

The company's financial results for Q3FY26 showcase substantial improvement across key performance indicators:

Segment-wise Performance Analysis

The company operates through two primary business segments, both contributing to the overall growth:

Plastic Segment

The plastic segment generated revenue of ₹1,423.44 lakhs during Q3FY26, with segment results of ₹313.18 lakhs. For the nine-month period, this segment achieved revenue of ₹3,459.07 lakhs with results of ₹520.74 lakhs.

Hygiene Segment

The hygiene segment contributed ₹653.23 lakhs in revenue for Q3FY26, with segment results of ₹42.98 lakhs. The nine-month performance showed revenue of ₹2,066.75 lakhs and results of ₹426.63 lakhs.

Nine-Month Performance Highlights

The company's cumulative performance for the nine months ended December 31, 2025, demonstrates sustained growth:

Cost Management and Operational Efficiency

The company demonstrated effective cost management during the quarter. Cost of material consumed increased to ₹1,571.85 lakhs from ₹919.08 lakhs in Q3FY25, primarily due to higher production volumes. Employee benefits expense rose marginally to ₹147.43 lakhs from ₹139.61 lakhs, while finance costs increased to ₹138.29 lakhs from ₹51.61 lakhs, reflecting business expansion activities.

Balance Sheet Strength

As of December 31, 2025, the company maintained a robust balance sheet with total assets of ₹9,627.90 lakhs. The paid-up equity share capital stood at ₹1,314.93 lakhs with a face value of ₹10 per share. Reserves excluding revaluation reserves increased significantly to ₹1,737.80 lakhs compared to negative ₹6.69 lakhs in the previous year.

Corporate Governance and Compliance

The financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on February 11, 2026. The statutory auditors GDK & Associates conducted a limited review of the results and provided an unqualified review report, confirming compliance with applicable accounting standards and regulatory requirements under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.